Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. is positioned favorably due to its strong clinical results from the FSdC program, which exhibited statistically significant and sustained improvements compared to traditional fibroblast approaches, especially in treating chronic spinal conditions. The company's advantageous positioning is further supported by preclinical data indicating that fibroblast spheroid-derived therapies demonstrate superior recovery and protection against degeneration in models of degenerative disc disease, suggesting a potential for disease-modifying therapy. Additionally, advancements in the therapeutic pipeline, including the promising Phase 1/2 development of CYPS317 for psoriasis, indicate robust market opportunities and reduced risk associated with FibroBiologics' strategic expansion into high-burden musculoskeletal markets.

Bears say

FibroBiologics faces significant risks related to the potential failure of its developmental candidates to meet peak commercial revenue estimates, primarily due to challenges in market size, penetration rates, and pricing strategies. Moreover, the company may struggle to secure necessary capital resources to sustain ongoing operations, which could hinder its ability to continue program development and commercialization efforts. Additionally, uncertainties surrounding the timing of warrant exercises and conversion of gold proceeds may adversely affect the company's liquidity and overall capital runway, creating further financial instability.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.